Research groups
Research Theme
Tumour Microenvironment (Lead Principal Investigator)
COLLABORATORS
Chris Schofield, Department of Chemistry, University of Oxford
Ester Hammond, Department of Oncology, University of Oxford
Monica Olcina, Department of Oncology, University of Oxford
Kevin Harrington, Institute of Cancer Research, London
Colleges
Geoff Higgins
MBChB, MRCP, FRCR, DPhil
Professor of Clinical Oncology
- Malcolm and Margaret Howat Professor of Clinical Oncology
- Honorary Consultant Clinical Oncologist, Oxford University Hospitals NHS Trust
Research Summary
Our group’s aim is to develop strategies to increase the efficacy of radiotherapy treatment. This work often involves repurposing existing compounds, or developing new treatments, that can be effectively combined with radiotherapy. Where possible, we seek to translate our laboratory findings into clinical trials utilising functional imaging and genomic data to provide signals of pharmacodynamic efficacy.
Biography
Geoff Higgins is the Malcolm & Margaret Howat Professor in Clinical Oncology.
He obtained degrees in pharmacology (1997) and medicine (2000) from Edinburgh University and undertook specialist training in Clinical Oncology at the Edinburgh Cancer Centre. He subsequently moved to Oxford and was awarded a Royal College of Radiologists/CRUK Clinical Research Fellowship leading to a DPhil in 2010. Geoff subsequently obtained his Clinician Scientist and Advanced Clinician Scientist Fellowships from Cancer Research UK.
His research includes laboratory and clinical research aiming to improve the efficacy of radiotherapy treatment. He is currently the Chief Investigator of two clinical trials and is joint-lead investigator of the CRUK National Cancer Imaging Translational Accelerator.
CURRENT GROUP MEMBERS
Laboratory Research:
Gonzalo Rodriguez-Berriguete, Senior Postdoctoral Researcher
Celia Gotorbe, Postdoctoral Researcher
Puru Thambiayah, DPhil student
Nicole Machado, DPhil Student
Wing Yu Lee, MRes Student
Clinical Research:
Robert Rulach, Consultant Radiation Oncologist
Daniel McGowan, Postdoctoral Researcher
Kelley Ferreira, NPL Physicist and DPhil Student
Daniel Murray, Senior radiotherapy dosimetrist and DPhil student
GROUP ALUMNI & NEXT DESTINATIONS
Giovanna Granata (DPhil Student 2016-2020) – Postdoctoral Researcher, Amsterdam UMC
James Coates (DPhil Student 2015-2019) – Postdoctoral Researcher, Harvard University
Kate Herbert (Postdoctoral Researcher 2015-2019) – Postdoctoral Researcher, University of Glasgow
Michael Skwarski (Clinical Research Fellow 2016-2019) – Consultant Clinical Oncologist, Guy’s Hospital, London
Tom Ashton (Postdoctoral Researcher 2011-2017) – Senior Scientist, Adaptimmune Therapeutics
Daniel McGowan (DPhil Student 2013-2016) – NIHR Clinical Lecturer and Medical Physicist, Oxford
Giacomo Pirovano (DPhil student 2012-2015) – Postdoctoral Researcher, Memorial Sloan Kettering Cancer Centre, New York
Gagan Tiwana (DPhil Student 2012-2015) – Senior Scientist, Horizon Discovery
Key publications
ntitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models.
Journal article
Rodriguez-Berriguete G. et al, (2024), Cell Death Dis, 15
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.
Journal article
Rodriguez-Berriguete G. et al, (2023), Clin Cancer Res, 29, 1631 - 1642
POLQ seals post-replicative ssDNA gaps to maintain genome stability in BRCA-deficient cancer cells.
Journal article
Belan O. et al, (2022), Mol Cell, 82, 4664 - 4680.e9
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Journal article
Zatreanu D. et al, (2021), Nat Commun, 12
Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer.
Journal article
Skwarski M. et al, (2021), Clin Cancer Res, 27, 2459 - 2469
Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress.
Journal article
Herbert KJ. et al, (2021), Cell Death Differ, 28, 1333 - 1346
Recent publications
Supplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Figure 1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Figure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Supplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Figure 4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2025)
Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting.
Journal article
McAteer MA. et al, (2025), BMC Med, 23
Deep learning-assisted interactive contouring of lung cancer: Impact on contouring time and consistency.
Journal article
Trimpl MJ. et al, (2024), Radiother Oncol, 200
Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action.
Journal article
O'Connor JPB. et al, (2024), Cancer Res Commun, 4, 2565 - 2574
UPR-induced intracellular C5aR1 promotes adaptation to the hypoxic tumour microenvironment by regulating tumour cell fate
Preprint
Suwa T. et al, (2024)
The Proteogenomics of Prostate Cancer Radioresistance.
Journal article
Haas R. et al, (2024), Cancer Res Commun, 4, 2463 - 2479
Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.
Journal article
Charlton PV. et al, (2024), Prostate, 84, 977 - 990
Data-driven gating (DDG)-based motion match for improved CTAC registration.
Journal article
Cook EL. et al, (2024), EJNMMI Phys, 11
ntitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models.
Journal article
Rodriguez-Berriguete G. et al, (2024), Cell Death Dis, 15
Repurposing radiosensitising medicines for radiotherapy: an overview.
Journal article
Low JM. et al, (2024), BMJ Oncol, 3
Potential Link between Hypoxic Status of Tumors and Surgical Outcomes in NSCLC Patients
Journal article
Low JM. et al, (2024), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 120, E42 - E43
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities.
Journal article
Machado ND. et al, (2023), Br J Cancer, 129, 897 - 899
Biallelic FBXW7 knockout induces AKAP8-mediated DNA damage in neighbouring wildtype cells.
Journal article
Chan DKH. et al, (2023), Cell Death Discov, 9
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.
Journal article
Rodriguez-Berriguete G. et al, (2023), Clin Cancer Res, 29, 1631 - 1642
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S6 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)
Correction to "Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta".
Journal article
Stockley ML. et al, (2023), J Med Chem
Timing of hypoxia PET/CT after 18F-Fluoromisonidazole injection in non-small cell lung cancer
Conference paper
Bourigault P. et al, (2023), RADIOTHERAPY AND ONCOLOGY, 182, S1859 - S1859
Timing of hypoxia PET/CT imaging after 18F-fluoromisonidazole injection in non-small cell lung cancer patients.
Journal article
Bourigault P. et al, (2022), Sci Rep, 12
POLQ seals post-replicative ssDNA gaps to maintain genome stability in BRCA-deficient cancer cells.
Journal article
Belan O. et al, (2022), Mol Cell, 82, 4664 - 4680.e9
The role of [18F]fluorodopa positron emission tomography in grading of gliomas.
Journal article
Roach JR. et al, (2022), J Neurooncol, 160, 577 - 589
Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models
Preprint
Rodriguez-Berriguete G. et al, (2022)
mated 96-well format high throughput colony formation assay for siRNA library screen.
Journal article
Hatch SB. et al, (2022), STAR Protoc, 3
Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours.
Journal article
Farrer NJ. et al, (2022), Br J Cancer, 126, 1241 - 1243
Elucidating the role of transiently hypoxic tumour cells on radiation resistance.
Journal article
Higgins GS. and Hammond EM., (2022), Br J Cancer, 126, 971 - 972
dvancing imaging biomarker development and translation through the National Cancer Imaging Translational Accelerator (NCITA)
Internet publication
Duric MA. and HIGGINS G., (2022)
dvancing imaging biomarker development and translation through the National Cancer Imaging Translational Accelerator (NCITA)
Internet publication
Duric M. and HIGGINS G., (2022)
dvancing imaging biomarker development and translation through the National Cancer Imaging Translational Accelerator (NCITA)
Other
McAteer M. and HIGGINS G., (2022)
Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia.
Journal article
Johanssen T. et al, (2022), Front Oncol, 12
Development of DNA polymerase theta inhibitors as tumour specific radiosensitisers
Conference paper
Prevo R. et al, (2022), RADIOTHERAPY AND ONCOLOGY, 170, S371 - S372
Survival Outcomes Following Concomitant Chemoradiation (CRT) for Stage III Non-small Cell Lung Cancer (NSCLC) at Oxford University
Conference paper
Johnstone P. et al, (2022), CLINICAL ONCOLOGY, 34, E1 - E1
basis for combining atovaquone-mediated hypoxia alleviation with immunotherapy plus radiotherapy
Conference paper
Rodriguez-Berriguete G. et al, (2022), RADIOTHERAPY AND ONCOLOGY, 170, S113 - S114
Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients.
Journal article
Bourigault P. et al, (2021), EJNMMI Res, 11
The protease SPRTN and SUMOylation coordinate DNA-protein crosslink repair to prevent genome instability.
Journal article
Ruggiano A. et al, (2021), Cell Rep, 37
ssociations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset.
Journal article
Vivekanandan S. et al, (2021), Radiother Oncol, 165, 119 - 125
Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers.
Journal article
McAteer MA. et al, (2021), Br J Cancer, 125, 1462 - 1465
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Journal article
Zatreanu D. et al, (2021), Nat Commun, 12
Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer.
Journal article
Skwarski M. et al, (2021), Clin Cancer Res, 27, 2459 - 2469
Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress.
Journal article
Herbert KJ. et al, (2021), Cell Death Differ, 28, 1333 - 1346
Survival outcomes following concomitant chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC) at Oxford University Hospitals (OUH) NHS Trust
Conference paper
Johnstone P. et al, (2021), LUNG CANCER, 156, S36 - S36
SPRTN protease and SUMOylation coordinate DNA-protein crosslink repair to prevent genome instability
Journal article
RAMADAN K., (2020), BioRXiv
External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.
Journal article
Pokrovska TD. et al, (2020), Cancers (Basel), 12
Corrigendum: Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?
Journal article
Wilson JD. et al, (2020), Front Oncol, 10
The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress.
Journal article
Coates JTT. et al, (2020), Cell Death Discov, 6
Stereotactic ablative radiotherapy (SABR) for early stage, non -small cell lung cancer (NSCLC): two year clinical outcome data from the Oxford Cancer Centre (OCC)
Conference paper
Pascal L. et al, (2020), LUNG CANCER, 139, S33 - S33
Repurposing Atovaquone as a Tumor Hypoxia Modifier: A Window of Opportunity Study in Patients with Resectable Non-small Cell Lung Cancer
Conference paper
Skwarski M. et al, (2020), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 108, S173 - S173
pilot dual-platform transcriptomic analysis of diagnostic prostate biopsies & radical RT response
Conference paper
Charlton P. et al, (2020), RADIOTHERAPY AND ONCOLOGY, 152, S610 - S611
Reply to 'The use of buparlisib as a radiosensitiser: What about toxicity?'.
Journal article
McGowan DR. et al, (2019), Eur J Cancer, 119, 196 - 197
[18F]FE-OTS964: a Small Molecule Targeting TOPK for In Vivo PET Imaging in a Glioblastoma Xenograft Model.
Journal article
Pirovano G. et al, (2019), Mol Imaging Biol, 21, 705 - 712
Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.
Journal article
Wu X. et al, (2019), Prostate, 79, 1079 - 1089
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Journal article
McGowan DR. et al, (2019), Eur J Cancer, 113, 87 - 95
Tumor pH and Protein Concentration Contribute to the Signal of Amide Proton Transfer Magnetic Resonance Imaging.
Journal article
Ray KJ. et al, (2019), Cancer Res, 79, 1343 - 1352
Targeting tumour hypoxia: shifting focus from oxygen supply to demand.
Journal article
Coates JT. et al, (2019), Br J Radiol, 92
Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?
Journal article
Wilson JD. et al, (2019), Front Oncol, 9
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
Journal article
Herbert KJ. et al, (2018), Cell Death Dis, 9
Safety and tumour hypoxia modifying effect of buparlisib with radiotherapy in NSCLC: a phase I dose escalation study
Conference paper
McGowan DR. et al, (2018)
Nucleoporin 54 contributes to homologous recombination repair and post-replicative DNA integrity.
Journal article
Rodriguez-Berriguete G. et al, (2018), Nucleic Acids Res, 46, 7731 - 7746
Whole tumor kinetics analysis of 18F-fluoromisonidazole dynamic PET scans of non-small cell lung cancer patients, and correlations with perfusion CT blood flow.
Journal article
McGowan DR. et al, (2018), EJNMMI Res, 8
Oxidative Phosphorylation as an Emerging Target in Cancer Therapy.
Journal article
Ashton TM. et al, (2018), Clin Cancer Res, 24, 2482 - 2490
4D-PET reconstruction using a spline-residue model with spatial and temporal roughness penalties.
Journal article
Ralli GP. et al, (2018), Phys Med Biol, 63
Validation of the survival model including cardiac substructure dosimetry in NSCLC
Conference paper
Vivekanandan S. et al, (2018), RADIOTHERAPY AND ONCOLOGY, 127, S383 - S384
Biological Precision in Radiotherapy
Conference paper
McKenna G. et al, (2018), RADIOTHERAPY AND ONCOLOGY, 127, S287 - S288
Beyond PARP-POLθ as an anticancer target.
Journal article
Higgins GS. and Boulton SJ., (2018), Science, 359, 1217 - 1218
CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner.
Journal article
Prevo R. et al, (2018), Cell Cycle, 17, 1513 - 1523
Impact of radical radiotherapy in lung cancer an assessment of cardiac and pulmonary volume changes in patients with locally advanced non-small cell lung cancer following radical radiotherapy
Conference paper
Ottewill C. et al, (2018), LUNG CANCER, 115, S72 - S72
IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer.
Journal article
Aleksic T. et al, (2017), Br J Cancer, 117, 1600 - 1606
18 F-fluoromisonidazole uptake in advanced stage non-small cell lung cancer: A voxel-by-voxel PET kinetics study.
Journal article
McGowan DR. et al, (2017), Med Phys, 44, 4665 - 4676
TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.
Journal article
Pirovano G. et al, (2017), Br J Cancer, 117, 503 - 512
4D-PET reconstruction of dynamic non-small cell lung cancer [18-F]-FMISO-PET data using adaptive-knot cubic B-splines
Conference paper
Ralli GP. et al, (2017), Proceedings - International Symposium on Biomedical Imaging, 1189 - 1192
F-fluoromisonidazole uptake in advanced stage non-small cell lung cancer: a voxel-by-voxel PET kinetics study
Journal article
McGowan D. et al, (2017), Medical Physics
Depletion of signal recognition particle 72kDa increases radiosensitivity.
Journal article
Prevo R. et al, (2017), Cancer Biol Ther, 18, 425 - 432
Optimization of Image Reconstruction for 90Y Selective Internal Radiotherapy on a Lutetium Yttrium Orthosilicate PET/CT System Using a Bayesian Penalized Likelihood Reconstruction Algorithm.
Journal article
Rowley LM. et al, (2017), J Nucl Med, 58, 658 - 664
Software Respiratory Gating of Positron Emission Tomography-Computed Tomography Improves Pulmonary Nodule Detection.
Journal article
Morley NCD. et al, (2017), Am J Respir Crit Care Med, 195, 261 - 262
new roadmap to improve translation of imaging biomarkers.
Journal article
Skwarski M. and Higgins GS., (2016), Br J Cancer, 115, 1443 - 1444
Uncovering the influence of the FGFR1 pathway on glioblastoma radiosensitivity.
Journal article
Sayal KK. et al, (2016), Ann Transl Med, 4
Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials.
Journal article
Ramroth J. et al, (2016), Int J Radiat Oncol Biol Phys, 96, 736 - 747
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia.
Journal article
Ashton TM. et al, (2016), Nat Commun, 7
le for human homologous recombination factors in suppressing microhomology-mediated end joining.
Journal article
Ahrabi S. et al, (2016), Nucleic Acids Res, 44, 5743 - 5757
Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.
Journal article
Coleman CN. et al, (2016), Clin Cancer Res, 22, 3138 - 3147
Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors.
Journal article
Higgins GS. et al, (2016), Recent Results Cancer Res, 198, 107 - 122
18F-Misonidazole PET-CT scan detection of occult bone metastasis.
Journal article
McGowan DR. et al, (2016), Thorax, 71
In Vitro-Pooled shRNA Screening to Identify Determinants of Radiosensitivity.
Journal article
Ceroni A. et al, (2016), Methods Mol Biol, 1470, 103 - 119
dit of palliative whole brain radiotherapy (WBRT) in patients with non-small cell lung cancer (NSCLC) treated at the Oxford Cancer Centre over 21/2 years
Journal article
Shakir R. et al, (2016), LUNG CANCER, 91, S52 - S53
Identification of vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen.
Journal article
Tiwana GS. et al, (2015), Oncotarget, 6, 5978 - 5989
Drug radiotherapy combinations: review of previous failures and reasons for future optimism.
Journal article
Higgins GS. et al, (2015), Cancer Treat Rev, 41, 105 - 113
Effect of PI3K-Inhibition on Normal Lung Tissue Following Irradiation in a Murine Model
Conference paper
Eccles CL. et al, (2015), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, E536 - E536
High throughput biological screens and their translation to new targets
Conference paper
McKenna WG. et al, (2015), RADIOTHERAPY AND ONCOLOGY, 115, S285 - S285
Stereotactic ablative radiotherapy (SABR) for early stage, medically inoperable non-small cell lung cancer (NSCLC): initial outcomes from 2 years' experience at the Oxford Cancer Centre, Oxford University Hospitals NHS Trust
Journal article
Hill E. et al, (2015), LUNG CANCER, 87, S47 - S47
igh-throughput siRNA screen identifies several novel determinants of tumour radiosensitivity
Conference paper
Tiwana G. et al, (2014), RADIOTHERAPY AND ONCOLOGY, 111, S94 - S94
Safety and Survival of High Dose Palliative Radiotherapy for Locally Advanced Lung Cancer
Journal article
O'Cathail SM. et al, (2014), CLINICAL ONCOLOGY, 26, S6 - S7
Safety and survival of high dose palliative radiotherapy for locally advanced lung cancer
Journal article
O'Cathail SM. et al, (2014), LUNG CANCER, 83, S55 - S56
Loss of function screens to identify novel radiotherapy targets
Conference paper
Higgins G. et al, (2014), RADIOTHERAPY AND ONCOLOGY, 111, S82 - S82
High throughput screening for genetic determinants of radiosensitivity
Conference paper
McKenna WG. et al, (2013), EUROPEAN JOURNAL OF CANCER, 49, S39 - S39
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.
Journal article
Fokas E. et al, (2012), Radiat Oncol, 7
Improved Outcomes With Dose Escalated Hypofractionated Radiotherapy for Prostate Cancer
Conference paper
Mackenzie J. et al, (2011), EUROPEAN JOURNAL OF CANCER, 47, S495 - S495
Overexpression of POLQ confers a poor prognosis in early breast cancer patients.
Journal article
Higgins GS. et al, (2010), Oncotarget, 1, 175 - 184
small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown.
Journal article
Higgins GS. et al, (2010), Cancer Res, 70, 2984 - 2993
POLQ (DNA polyermase theta) as a novel therapeutic target: preclinical and clinical data
Conference paper
Higgins GS. et al, (2010), EJC SUPPLEMENTS, 8, 106 - 106
Small Interfering RNA Screen of Genes Involved in DNA Repair Identifies Tumor-Specific Radiosensitization by POLQ Knockdown
Journal article
Higgins GS. et al, (2010), CANCER RESEARCH, 70
Conventional radiotherapy or hypofractionation? A study of molecular changes resulting from different radiation fractionation schemes.
Journal article
Hamilton J. et al, (2009), Cancer Biol Ther, 8, 774 - 776
Non-small-cell lung cancer dimensions: CT-pathological correlation and interobserver variation.
Journal article
Macpherson RE. et al, (2009), Br J Radiol, 82, 421 - 425
Possible Radiation Sensitisation by Trastuzumab Leading to Radiation-Induced Myelitis.
Journal article
Law AB. et al, (2009), Breast Care (Basel), 4, 40 - 42
long and winding road: the role of chemotherapy for hormone-refractory prostate cancer.
Journal article
Higgins GS. et al, (2007), Int J Clin Pract, 61, 1964 - 1965
naemia prevalence and blood transfusion rates in patients receiving chemoradiation for head and neck cancer
Conference paper
Higgins G. and Junor E., (2007), RADIOTHERAPY AND ONCOLOGY, 82, S48 - S48
Survival and PSA relapse data after hypofiractionated radiotherapy for early stage prostate cancer
Conference paper
Law A. et al, (2007), EJC SUPPLEMENTS, 5, 296 - 296
Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.
Journal article
Higgins GS. et al, (2006), Int J Radiat Oncol Biol Phys, 65, 982 - 989
Myxopapillary ependymoma with intracranial metastases.
Journal article
Higgins GS. et al, (2005), Br J Neurosurg, 19, 356 - 358